Case Report

Topiramate-induced hyperammonemonic encephalopathy in a patient with mental retardation: A case report and review of the literature

Sahawat Tantikittichaikul a,⁎, Justine Johnson b, PavisLaeangvejkal a, John DeToledo a

a Texas Tech University Health Sciences Center, Department of Neurology, 3601 4th Street, STOP 8321, Lubbock 79430, TX, USA
b Texas Tech University Health Sciences Center, School of Medicine, 3601 4th Street, Lubbock 79430, TX, USA

**A R T I C L E  I N F O**

Article history:
Received 21 July 2014
Received in revised form 31 August 2014
Accepted 1 September 2014
Available online xxxx

Keywords:
Topiramate
Hyperammonemia
Encephalopathy
Complication

**A B S T R A C T**

Hyperammonemia is an uncommon side effect of topiramate (TPM) that has only been reported when it is used as an adjunct to valproate. We report a patient with mental retardation who developed reversible encephalopathy from TPM. Ammonia level was monitored during the course of TPM treatment. This patient had recurring, reversible elevations in serum ammonia levels that coincided with the administration of TPM. To our knowledge, symptomatic hyperammonemia has not been reported to occur with TPM monotherapy.

© 2014 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by/3.0/).

1. Introduction

Metabolic encephalopathy poses a challenging diagnosis to neurologists because of the condition’s varied and potentially reversible etiologies. Drug-induced metabolic encephalopathies are common but often go unrecognized. This is unfortunate as the correct identification of the cause and discontinuation of the offending agent usually result in quick and complete resolution of the symptoms. As a group, antiepileptic drugs are a relatively common cause of encephalopathy, either by direct CNS effect, or, in some cases, by inducing hyperammonemia. This is a well-established complication of valproic acid and has now been reported to occur in patients previously treated with valproic acid to which TPM was added [1–8]. Topiramate is a broad-spectrum anticonvulsant that is also extensively used for migraine prophylaxis, as a mood stabilizer, and for alcohol dependency. When given as monotherapy, the use of TPM can be associated with cognitive impairment, glaucoma, and kidney stones. Hyperammonemia has not been reported with the use of TPM monotherapy.

There was no clinical or laboratory evidence of inborn errors of metabolism. At baseline, the patient had moderate developmental delay and was able to feed himself, use the restroom on his own, communicate using a few words, and ambulate without assistance. Topiramate 100 mg bid had been started to treat mood disorder. Over a two-week period preceding admission, he stopped talking and was noted to have increasing gait instability and generalized weakness. He became unable to feed himself and became incontinent of urine. Examination on admission showed the patient to be lethargic but aroused. His language output was limited to him repeating the words “fine–fine” whenever he was asked a question. Cranial nerve exam was notable for gaze-evoked nystagmus on lateral gaze bilaterally. The patient was hyperreflexic with 3⁺ reflexes of all four extremities. He was ataxic and had gait instability. No asymmetry of the motor exam and no asterixis were observed.

The patient arterial ammonia was elevated at 77 µmol/l (upper limit of normal = 60 µmol/l) on admission. The rest of the laboratory test results were normal including other liver function tests and hepatitis panel. Electroencephalogram on admission showed generalized background slowing without triphasic waves or epileptiform discharge. Brain MRI showed generalized brain atrophy without abnormalities in the white matter or cortex. The initial diagnostic impression was hyperammonemonia-induced encephalopathy. He was treated with lactulose, and TPM was discontinued on the first day of admission. No other medication changes were carried out. Within two days, mental state changes resolved, and staff who were familiar with the patient felt that he was back to his baseline. Repeat ammonia level the following day was 27 µmol/l. On the third day of admission, the patient had a 2213–3232/© 2014 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by/3.0/).
partial seizure presenting as a behavior arrest and clonic movements of the right side of the face and the right arm. Topiramate was restarted at the same dosage as before. The seizures did not reoccur, but repeat ammonia levels over the ensuing two days showed a trend upwards, 47 μmol/l and 57 μmol/l, respectively. Given the fact that ammonia levels were again elevated with TPM, it was switched to lamotrigine (LTG). Twenty-four hours after the discontinuation of TPM, serum ammonia again decreased to 33 μmol/l.

3. Discussion

Topiramate was originally synthesized as a potential hypoglycemic agent [9]. Although the drug did not show hypoglycemic activity, it showed a wide range of CNS effects, acting as an antagonist of voltage-activated Na⁺ channels, L-type voltage-activated Ca²⁺ channels, carbonic anhydrase (CA) isozymes, and AMPA/kainate receptors. Subsequently, it was also shown to be a GABA<sub>a</sub> agonist, and that paved the way to its use as an anticonvulsant. Although the use of TPM can be associated with cognitive symptoms, this side effect appears to be due to a direct effect of the drug in the CNS and is not secondary to any metabolic abnormality. Hyperammonemia secondary to the combined use of TPM and other antiepileptic drugs, particularly VPA, has been reported but is probably not common, with only a few cases reported in the literature [1–8].

3.1. Mechanism of topiramate-related hyperammonemia

To our knowledge, this is the first case of a TPM-induced hyperammonemia, without the use of any concurrent AEDs, to be reported. Whereas the hyperammonemia seen in cases of the combination of VPA and TPM appears to be related to interference with glycine metabolism and metabolic acidosis, the mechanism by which TPM itself would cause hyperammonemia is unknown. There are two major mechanisms that might contribute to this effect: 1) TPM is a carbonic anhydrase inhibitor and can decrease the production of bicarbonate (HCO₃⁻), which is required in the synthesis of carbamoyl phosphate, an intermediate substrate in the urea cycle, and 2) the other direct effect of TPM is the reduction of the activity of glutamine synthetase, the main enzyme for the detoxification of ammonia [10].

3.2. Hyperammonemic encephalopathy

Hyperammonemic encephalopathy has been thoroughly described in the literature. Clinical symptoms are varied and include nausea, vomiting, seizures, ataxia, abnormal behavior, or coma, depending on the ammonia level and age of the patient [11,12]. Venous ammonia level may correlate less with clinical symptoms compared with arterial ammonia level [13–15]. This patient presented with a two-week history of mental status changes and psychomotor decline. He also exhibited ataxia, nystagmus, and gait instability and one episode of complex partial seizures during admission. The short duration of his recent symptoms and the fact that all symptoms fully reversed indicated that none of his recent symptoms were caused by progression of an underlying CNS pathology. Other common etiologies of mental status changes in patients with developmental delay such as toxic, metabolic, infectious, and subacute structural CNS lesions were also ruled out. Computerized tomography scan and MRI of the brain, EEG, renal function, electrolytes, complete blood count, thyroid function, urine analysis, and sepsis workup were all negative. The patient’s EEG showed mild slowing of the background but no epileptiform abnormalities or triphasic waves. After discontinuation of TPM, the patient returned to his baseline with resolution of the ataxia and nystagmus.

Although hyperammonemia may reflect an underlying abnormal urea cycle defect (UCD), this did not appear to be the cause in this patient. No abnormalities suggestive of UCD had been detected in previous evaluations looking for the etiology of his developmental delay. Although some UCD may become manifested later in life, these cases typically do not have developmental delay. For these reasons, we do not believe that the development of TPM-induced hyperammonemia was due to an “unmasking” of an underlying UCD.

Conflict of interest

The authors declare no conflict of interest.

References

[1] Longin E, Teich M, Koefen W, Koeng S. Topiramate enhances the risk of valproate-associated side effects in three children. Epilepsia Apr 2002;43(4):451–4.
[2] Latour P, Biraben A, Polard E, Bentue-Ferrer D, Beauplet A, Tribut O, et al. Drug induced encephalopathy in six epileptic patients: topiramate? Valproate? Or both? Hum Psychopharmacol Apr 2004;19(3):193–203.
[3] Cheung E, Wong V, Fung CW. Topiramate–valproate-induced hyperammonemic encephalopathy syndrome: case report. J Child Neurol Feb 2005;20(2):157–60.
[4] Deutsch S, Burket JA, Rosse RB. Valproate-induced hyperammonemic encephalopathy and normal liver functions: possible synergism with topiramate. Clin Neuropsychopharmacol Nov 2009;32(6):350–2.
[5] Vivekanandan S, Nayak SD. Valproate-induced hyperammonemic encephalopathy enhanced by topiramate and phenobarbitone: a case report and an update. Ann Indian Acad Neurol Apr 2010;13(2):145–7.
[6] Gomez-Ibanez A, Urrestarazu-Bolumburu E, Viteri-Torres C. Hyperammonemic encephalopathy related to valproate, phenobarbital, and topiramate synergism. Epilepsy Behav Aug 2011;21(4):480–2.
[7] Canso-Zaleta A, Hernandez-Ortiz OH, Gonzalez-Gonzalez CA, Amares S. Report of three cases of hyperammonaemic encephalopathy associated with valproic acid due to possible synergism with phenobarbital and topiramate. 1 Farm Hosp Sep 2012;36(5):441–2.
[8] Blackford MG, Do ST, Enlow TC, Reed MD. Valproic acid and topiramate induced hyperammonemic encephalopathy in a patient with normal serum carnitine. J Pediatr Pharmacol Ther Apr 2013;18(2):128–30.
[9] Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000;41(Suppl. 1):S3–9.
[10] Fraser CM, Sills GJ, Forrest G, Thompson GG, Brodie MJ. Effects of anti-epileptic drugs on glutamine synthetase activity in mouse brain. Br J Pharmacol Apr 1999;126(7):1634–8.
[11] Clay AS, Hainline BE. Hyperammonemia in the ICU. Chest Oct 2007;132(4):1368–78.
[12] Auron A, Brophy PD. Hyperammonemia in review: pathophysiology, diagnosis, and treatment. Pediatr Nephrol Feb 2012;27(2):207–22.
[13] Huzienza JR, van Dam GM, Gips CH. Arterial ammonia with Blood Ammonia Checker II and with indophenol reaction to assess presence of hepatic encephalopathy. Clin Chim Acta Aug 15 1996;252(1):73–82.
[14] Ono J, Aggarwal A, Krieger D, Easley KA, Karafa MT, Van LF, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med Feb 15 2003;114(3):188–93.
[15] Drolz A, Jager B, Wewalka M, Saxa R, Horvatić T, Roedl K, et al. Clinical impact of arterial ammonia levels in ICU patients with different liver diseases. Intensive Care Med Jul 2013;39(7):1227–37.